Identifying vulnerabilities to immune checkpoint inhibitors of oncogene-addicted non-small cell lung cancer subgroups

被引：0
|
作者：
Diaz-Cano, Ines [1 ,2 ]
Gracia, Jose [1 ]
Cozar, Patricia [1 ]
Revuelta, Belen [1 ]
Carrizo, Nuria [1 ]
Dubrot, Juan [3 ]
Paz-Ares, Luis [1 ,2 ,4 ]
Otano, Itziar [1 ,2 ]
机构：
[1] Spanish Natl Canc Res Ctr CNIO, H12O CNIO Lung Canc Clin Res, Hlth Res Inst Hosp 12 Octubre Imas12, Madrid, Spain
[2] Spanish Ctr Biomed Res Network Oncol CIBERONC, Madrid, Spain
[3] Univ Navarra, Solid Tumors Program, Div Oncol, Ctr Appl Med Res CIMA, Pamplona, Spain
[4] Univ Complutense Madrid, Dept Med & Physiol, Madrid, Spain
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2024年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
2191 - P1.
引用
收藏
页码：792 / 792
页数：1
相关论文
共 50 条
  • [41] Immune checkpoint inhibitors in therapy of non-small cell lung cancer (a review)
    Kolesnik, O. P.
    Mykhailychenko, V. V.
    ZAPOROZHYE MEDICAL JOURNAL, 2021, 23 (03) : 418 - 425
  • [42] Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
    Wang, Shuai
    Hao, Jiatao
    Wang, Hao
    Fang, Yong
    Tan, Lijie
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [43] Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
    Zhenbin Qiu
    Zihao Chen
    Chao Zhang
    Wenzhao Zhong
    Experimental Hematology & Oncology, 8
  • [44] Stereotactic irradiation in targeted therapy of oligometastatic oncogene-addicted (non-small-cell) lung cancer
    Giraud, N.
    Abdiche, S.
    Trouette, R.
    CANCER RADIOTHERAPIE, 2019, 23 (04): : 357 - 358
  • [45] The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era
    Spagnuolo, Alessia
    Muto, Matteo
    Monaco, Fabio
    Colantuoni, Giuseppe
    Gridelli, Cesare
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (06) : 1134 - 1151
  • [46] Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications
    Toyokawa, Gouji
    Bersani, Francesca
    Bironzo, Paolo
    Picca, Francesca
    Tabbo, Fabrizio
    Haratake, Naoki
    Takenaka, Tomoyoshi
    Seto, Takashi
    Yoshizumi, Tomoharu
    Novello, Silvia
    Scagliotti, Giorgio, V
    Taulli, Riccardo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 184
  • [47] Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions
    Remon, J.
    Vilarino, N.
    Reguart, N.
    CANCER TREATMENT REVIEWS, 2018, 64 : 21 - 29
  • [48] Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?
    Schoenmaekers, Janna Josephus Anna Oda
    Paats, Marthe Sentijna
    Dingemans, Anne-Marie Clasina
    Hendriks, Lizza Elisabeth Lucia
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2599 - 2617
  • [49] Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer
    Romanidou, Ourania
    Landi, Lorenza
    Cappuzzo, Federico
    Califano, Raffaele
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (03) : 176 - 187
  • [50] Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases
    Wei Yuxi
    Xu Yan
    Wang Mengzhao
    中华医学杂志英文版, 2023, 136 (13)
12345